Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Since interferon-α and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed an exploratory study investigating the effects of a standard IM dose (400 mg/d) and a variable pegylated interferon-α (PegIFN) dose (50 μg/wk, 100 μg/wk, and 150 μg/wk). The criteria for dose adjustment were designed so as to ensure the delivery of the IM dose and to protect life quality. There were 76 patients with previously untreated Philadelphia (Ph)–positive CML enrolled in the study. There were 3 patients who discontinued IM and 45 patients who discontinued PegIFN. The severity of adverse events increased with increasing PegIFN dose. The IM dose could be administered to the patients who were assigned to receive 50 μg/wk or 100 μg/wk PegIFN but not to those who were assigned to receive 150 μg/wk. The median administered dose of PegIFN ranged between 32 μg/wk and 36 μg/wk. The cytogenetic response was 70% complete (Ph-neg 100%) and 83% major (Ph-neg > 65%). The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 2×
“Time from diagnosis to enrollment, mean (range), d 50 (9-90) 51 (10-90) 43 (9-90) 50 (14-90)”
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Schmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R., & Neubauer, A. (2001) · Blood · doi:10.1182/blood.v97.11.3648 · Cited by 77 · cited 3×
“patients (%) 24 (31) 9 (33) 4 (22) 11 (35)”
Deng, M., & Daley, G. Q. (2001) · Blood · doi:10.1182/blood.v97.11.3491 · Cited by 50
Cited by
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Self-citationThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903396469 · Cited by 126
Guilhot, F., Rigal-Huguet, F., Guilhot, J., Guerci-Bresler, A.-P., Maloisel, F., Rea, D., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2021) · Leukemia · doi:10.1038/s41375-020-01117-w · Cited by 30
Flygt, H., Söderlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., Lübking, A., Dreimane, A., Markevärn, B., et al. (2021) · European Journal of Haematology · doi:10.1111/ejh.13699 · Cited by 11
Metadata
- Authors
- Baccarani, M., Martinelli, G., Rosti, G., Trabacchi, E., Testoni, N., Bassi, S., Amabile, M., Soverini, S., Castagnetti, F., Cilloni, D., Izzo, B., de Vivo, A., Messa, E., Bonifazi, F., Poerio, A., Luatti, S., Giugliano, E., Alberti, D., Fincato, G., Russo, D., Pane, F., Saglio, G., & Leukemia, F. T. G. W. P. O. C. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-12-15
- Volume
- 104
- Issue
- 13
- Pages
- 4245-4251
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2131656137
- Cited by
- 106
- References
- 4
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2004-03-0826
- The paper
- Baccarani, M., Martinelli, G., Rosti, G., Trabacchi, E., Testoni, N., Bassi, S., Amabile, M., Soverini, S., Castagnetti, F., Cilloni, D., Izzo, B., de Vivo, A., Messa, E., Bonifazi, F., Poerio, A., Luatti, S., Giugliano, E., Alberti, D., Fincato, G., . . . Leukemia, F. T. G. W. P. O. C. M. (2004). Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood. https://doi.org/10.1182/blood-2004-03-0826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.